Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,263.82 +3,668.41 (+6.16%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
CSPC Pharmaceutical Group Limited (1093.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
At close: 04:08PM HKT
| Previous close | 6.710 |
| Open | 6.750 |
| Bid | 6.750 x 0 |
| Ask | 6.760 x 0 |
| Day's range | 6.650 - 6.790 |
| 52-week range | 5.200 - 8.140 |
| Volume | |
| Avg. volume | 39,833,655 |
| Market cap | 80.418B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 12.75 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.28 (4.14%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | N/A |
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
© 2024 Yahoo. All rights reserved.